The human enzyme paraoxonase-2 (PON2) has two functions, an enzymatic lactonase activity and the reduction of intracellular oxidative stress. 
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The human enzyme paraoxonase-2 (PON2) has two functions, an enzymatic lactonase activity and the reduction of intracellular oxidative stress. As a lactonase, it dominantly hydrolyzes bacterial signalling molecule 3OC12 and may contribute to the defence against pathogenic Pseudomonas aeruginosa. By its anti-oxidative effect, PON2 reduces cellular oxidative damage and influences redox signalling, which promotes cell survival. This may be appreciated but also deleterious, given that high PON2 levels reduce atherosclerosis but may stabilize tumour cells. Here (2) . Consequently, many strategies aim at reducing ROS back to physiological levels and mitochondria are centrally involved owing to their high potential in ROS production (3). Mitochondrial respiratory chain complexes are surrounded by anti-oxidative factors to suppress coincidental O 2 -generation by transfer of electrons to oxygen. However, O 2 -also serves an intended starting-point for apoptotic signalling, because O 2 -produced at the inner mitochondrial membrane is oxidized to H 2 O 2 , which gives rise to cardiolipin peroxidation, cytochrome C release, caspase activation and cell death (4) (5) (6) . Thus, alterations of these processes are twoedged and can lead to either prolonged survival or death, for which reason they are modified in several diseases (e.g. tumors) and targeted by pharmacological interventions. Interestingly, the human enzyme paraoxonase-2 (PON2) may serve a putative target gene, because it protects against atherosclerosis (7, 8) , but may also support apoptosis evasion by its anti-oxidative and anti-apoptotic function (9) (Witte et al., submitted). The paraoxonase family consists of three highly conserved proteins PON1, PON2 and PON3, which were structurally and experimentally identified as calcium-dependent, lactone hydrolyzing enzymes with variations in substrate specificity (10) (11) (12) (13) (14) . The PONs differ in localization, as PON1 mainly associates with circulating serum HDL particles, while the intracellular PON2 appears in two spliced isoforms that predominantly localize to the endoplasmic reticulum (ER), mitochondria and (peri)-nuclear region (7, 9, 15) . Endogenous substrates of PON2 are largely unknown, but it has been shown that its lactonase activity dominantly hydrolyzes the Pseudomonas aeruginosa signalling lactone 3OC12, for which reason PON2 may add to the anti-bacterial defence (16, 17) , a mechanism apparently sensitive to major calcium disturbances (18, 19) . Further, studies with PON2-deficient mice indicated that PON2 suppresses atherosclerosis and several studies described a significant ROSdiminishing function of PON2 in various cells (8, 9, 18, 20, 21) . Although fundamental to understanding PON2 function, it is yet unanswered if the lactonase activity and antioxidative function are interrelated. Also, mechanism and specificity of its anti-oxidative function are unresolved. These issues were addressed in the current study. We found that PON2 specifically diminished O 2 -released by both mitochondrial complexes-I and III at the inner mitochondrial membrane, presumably by acting on coenzyme Q10 (CoQ). In support, PON2 differs from superoxide dismutases (SODs) or vitamins in that it efficiently prevented O 2 -formation, but did not diminish O 2 -resulting from CoQ-independent sources. We further demonstrate independent functions of PON2, since mutants devoid of lactonase activity still exhibited full protection against ROS and apoptosis. Together with results indicating that PON2 shares the same hydrolytic mechanism as PON1, we reveal fundamental details of the function and mechanism of PON2.
Experimental Procedures Cells and materials-All experiments employed human endothelial EA.hy 926 cells with or without stable PON2-GFP expression (9, 19) . Dihydrorhodamine-123 (DHR123) and MitoSox Red were from Molecular Probes; 2,3-dimethoxy-1,4-naphthoquinone (DMNQ) and 3-morpholinosydnonimine (Sin1) were from Calbiochem; L-012 was from Wako Chemicals; Glycosidase-F was from Roche; 2-methyl-6-[pmethoxyphenyl]-3,7-dihydroimidazo[1,2-a]-pyrazin-3-one (MCLA) and all other reagents were from Sigma. Site-directed mutagenesis of PON2-We used QuikChange or Finnzymes site-directed mutagensis kits (Stratagene / New England Biolabs, respectively) according to the suppliers instructions with primers given in the supplement.
Sequenced plasmids were transfected as before (9) . Protein expression was verified by Western blotting; PON2-mutant-GFP cDNAs were re-sequenced.
Cell fractionation-Mitochondria were enriched according to standard procedures (see supplement). Membranes of fresh mitochondria were prepared by brief sonication and recentrifugation. ROS detection-Unless stated otherwise, ROS was detected as previously published (9, 18) .
Where indicated, cells were pre-treated with polyethylene-glycol (PEG)-coupled SOD (100 U/ml) or PEG-catalase (200 U/ml) for 24h. Sin-1 (10 µM)-induced ONOO -was detected by dihydrorhodamine (DHR-)123 (5 µM). H 2 O 2 was detected using the Fluoro-catalase kit (Cell Technology Inc.). To this end, cells were lysed in lysis-buffer-A (1% Triton X100, 200 mM NaCl, 100 mM Tris pH 7.4, HALT protease inhibitor (Pierce)) and 20 µg of protein were analyzed. H 2 O 2 was either added directly (40 µM) or was produced indirectly via O 2 -by xanthine / xanthine oxidase (X/XO; 200 µM / 5 mU). Similarly, ROS were measured in presence of recombinant human PON2 (rhPON2; Genway), or BSA. Alternatively, PON2-His 6 expressed in HEK293 cells was enriched by NiNTA chromatography (see supplement). Fractions containing PON2-His 6 were used with 2.5 µg protein / reaction or equal volumes of dialyzed eluates from mock-treated cells. Chemiluminescence was recorded before and after injection of xanthine (200 µM) to PBS + 1 mM CaCl 2 , rhPON2 or PON2-His 6 , 40 µM L-012 and xanthine oxidase (5 mU/ml). Also, O 2 -was measured by quantification of 2-hydroxyethidium by HPLC (modified from (22) ; see supplement). To detect mitochondrial O 2 -, samples were incubated with MitoSOX-Red (Mito-HE; 1 µM; 37°C; 20 min) in Hank's balanced salt solution (+Ca; +Mg), washed, stimulated with antimycin (15 µM) and analyzed in a plate-reader with excitation/emission at 405/580 nm, respectively. Alternatively, cells were loaded as before, stimulated (2h) with antimycin (15 µM) or rotenone (20 µM), detached, washed with chilled PBS, fixed in 2% paraformaldehyde and analyzed by a FACSAria cell-sorter (BD Biosciences; at 405/580nm). Mitochondria or membranes (0.25 µg protein / µl) were analyzed in 125 mM KCl, 10 mM HEPES pH 7.9, 5 mM MgCl 2 , 2 mM CaCl 2 , 2 mM K 2 HPO 4 , 5 mU xanthine oxidase, 5 µM MCLA; a luminometer recorded cumulative ROS production for 20s before and after injection of xanthine (200 mM). Alternatively, superoxide was induced with antimycin (15 µM), succinate (5 mM) or a-ketoglutarate (5 mM). SOD activity-Zymography was used according to standard procedures (see supplement). PON2 lactonase activity-Deglycosylation and determination of PON2 lactonase activity were previously published (9, 18) . Importantly, in every experiment, PON2-mutant expression levels were analyzed by Western blotting using a ChemiDoc XRS imaging system (Bio-Rad) equipped with QuantityOne 4.6.7 software, normalized to -tubulin and subsumed comparing to PON2-WT. Software, statistics, image acquisition-GraphPad Prism-5 was used for calculation or statistical evaluation using 1-or 2-way ANOVA and/or non-linear regression curve fitting. p<0.05 was considered significant. Adobe Photoshop was used for image acquisition. If necessary, only brightness and/or contrast were changed simultaneously for all areas of any blot. The accompanying supplemental file contains more detailed descriptions and unmentioned methods.
Results

PON2 indirectly but specifically diminishes O 2
--We previously showed that PON2 reduced DMNQ-generated ROS detected with carboxy-H 2 DCFDA or the luminol derivative L-012 (9), but these analyses were unable to deduce the particular radical diminished by PON2. Because pre-treatment with cell-permeable PEG-SOD but not PEG-catalase (to diminish O 2 -or H 2 O 2 , respectively) significantly lowered ROS levels in such analyses (Fig. 1A) , we concluded that PON2 diminished superoxide. To test this more directly, we used dihydroethidium (DHE), which under oxidative stress is oxidized to O 2 --specific 2-hydroxyethidium (2-HE) and unspecific ethidium. After cells were loaded with DHE and treated with DMNQ, significantly increased 2-HE levels were found in naïve, but not PON2-overexpressing cells (Fig. 1B) , which verifies above conclusion. PON2 appears specific for O 2 -because it did not alter levels of other radicals, namely H 2 O 2 and ONOO - (Fig.  1C+D) . To test for direct protein actions, O 2 -was generated in vitro by xanthine / xanthine oxidase (X/XO) in the presence of recombinant or mammalian PON2, but these PON2 preparations were indistinguishable from controls (Fig. 1E) . This implies an indirect mechanism of PON2 and the necessity of a co-factor -or, given the lack of redox-active centres, PON2 itself could serve a co-factor for other systems. However, the chief O 2 --diminishing activities of SOD1 and SOD2 were not changed by PON2 overexpression (Fig. 1F + below produced by complex-I ( Fig. 2A) , which releases O 2 -only to the matrix side (23) . This implies that PON2 acts on the matrix-side of the inner membrane, or it modulates coenzyme Q10 (CoQ) which shuttles electrons between the respiratory complexes. In support of the latter, mitochondrial membranes from PON2 overexpressing cells also produced less O 2 -when stimulated with succinate, which is oxidized by complex-II passing electrons to CoQ (Fig. 2B) -, but could not diminish this radical once it is produced. This was tested with CoQ-independent ROS sources: We stimulated mitochondrial membranes from naive or PON2 overexpressing cells with -ketoglutarate, which produces ROS from membrane-associated but CoQ-independent -ketoglutarate-dehydrogenase (25). Under such conditions, similar O 2 -levels were observed (Fig. 2C) . Likewise, when O 2 -was generated by X/XO, mitochondrial membranes from PON2 overexpressing cells were indistinguishable from controls (Fig. 2D) , in contrast to stimulation with succinate, rotenone or antimycin (above). Thus, PON2 suppresses O 2 -formation that involves CoQ, but it cannot scavenge O 2 -once it is formed. Further controls support this conclusion: First, cytochrome C can oxidize O 2 -to oxygen (26), but its expression was unchanged by PON2 (Fig. 2E ) and cytochrome C siRNA did not abrogate PON2's effect, albeit cytochrome C levels were reduced to ~60% (not shown). Second, PON2 did not increase O 2 -dismutation, since lysates from naïve or PON2 overexpressing cells had similar H 2 O 2 levels secondary to X/XO-generated O 2 - (Fig. 2F) . PON2 has independent activities-To test if ROS reduction is linked to enzymatic activity, we identified residues crucial to hydrolytic activity. PON2 shares ~60% identity with PON1. For PON1, key catalytic residues are known and its hydrolytic activity, but not glycosylation, is essential to its anti-atherogenic properties (11, (27) (28) (29) . We created point mutations in PON2 that correspond to the PON1 residues required for hydrolytic activity. Confocal microscopy of the GFP-tagged proteins revealed subcellular targeting identical to PON2-WT (not shown). To map PON2's glycosylation site, glycosidase treatment with subsequent Western blotting was applied to lysates from cells overexpressing PON2-WT, -N 254 A, -N 269 A, -N 323 A or -N 254+323 A (Fig. 3A) . Mass of PON2-N 269 A was similar to the WT, thus N 269 is not glycosylated. In contrast, PON2-N 254 A or -N 323 A migrated between glycosylated and deglycosylated PON2-WT and double mutant N 254+323 A was identical to deglycosylated PON2-WT. Thus PON2 is glycosylated on both N 254 and N 323 , which is consistent with Stoltz et al. (30) . To analyze PON2 activity, we used one of its putative natural substrates, 3OC12 (12, 16, 18) under conditions that estimate initial hydrolytic rates. For all experiments, activities were normalized to expression levels (see Methods) to exclude that differences result from dissimilar expression. Our previous studies showed 3OC12 activity is specific for PON2 in EA.hy 926 cells (16, 18 (11, 28) . A similar effect was observed with PON2-D 268 A, which likely disturbs binding of the catalytic calcium. This emphasizes the requirement of the two enzyme bound calcium ions, which adds to previous studies (11, 16) and suggests similar hydrolytic mechanisms of PON1 and PON2. But while glycosylation was dispensable for secretion and activity of PON1 (27) , Stoltz et al. showed that glycosylation of PON2 influenced lactonase activity (30) . In accord with the latter, we also found that PON2-N 254+323 A lacked activity (Fig.  3B) . To exclude lost activity resulted merely from disturbed initial folding due to lacking glycosylation, we also analyzed lysates with prior deglycosylation, upon which active PON2-WT again lost activity (not shown). In contrast to Stoltz et al. (30), however we did not observe any impact of natural polymorphism S/C 311 on 3OC12 hydrolysis (Fig. 3B) . We finally tested if mutations that abrogate lactonase activity also influence ROS reduction. Importantly, PON2-H 114 Q and -H 133 Q (and also -S 311 C) were similar to WT in their ability to reduce ROS (Fig. 4A) , which implies independent hydrolytic and anti-oxidative functions. Alike, additional experiments demonstrate direct mitochondrial functions of PON2-WT and -H 114 Q on steps subsequent to O 2 -formation (i.e. cardiolipin peroxidation, cytochrome C release etc.) suggesting that PON2's anti-apoptotic effect is based on ROS reduction (not shown / Witte et al., submitted); in accordance PON2-H 114 Q and / or PON2-H 133 Q equalled PON2-WT in preventing induction of apoptosis, which we here assessed by investigating activation of caspase-3, loss in intracellular ATP levels and by Annexin-V / 7-AAD flow cytometry (Fig. 4C -E,  respectively) . The fact that PON2-H 114 Q and PON2-H 133 Q prevented apoptosis somewhat better than PON2-WT agrees with their slightly better performance in reduction of ROS. Discussion ROS and RNS are not just harmful but also vital to cell function and some clinical trials demonstrated even augmented mortality after anti-oxidant treatment (31) (32) (33) . Hence, outcome of anti-oxidant treatment depends on overall context, cell-type, efficient targeting, nature of the radical species and its detoxification product. Previous reports on PON2 demonstrated its antioxidative function (8, 9, 18, 20) , but barely addressed targeting or specificity. Here we show that PON2 prevents O 2 -generation at the inner mitochondrial membrane presumably by modulating CoQ, which provides mechanistic insight into a cancer-related, anti-apoptotic function of PON2 (Witte et al., submitted). Studies with SOD1 -/-or SOD2 -/-mice revealed that mitochondrial O 2 -is far more detrimental than cytosolic O 2 -(34). SOD2 -/-mice suffered from neonatal death, defects in electron transport chain, reduced mitochondrial membrane potential, and enhanced cytochrome C release. So far, this has not been reported for the PON2-deficient mice (8) . As another difference we revealed that PON2 prevented O 2 -generation but was ineffective against existing radicals, while the reverse applies to SOD2. From such perspective, these enzymes may synergize to avert overwhelming mitochondrial O 2 -levels. We did not find an association of PON2 with distinct respiratory complexes and PON2 prevented O 2 -production from both complexes I and III, which together suggests a modulation of or interaction with CoQ. A PON2 mutant lacking solely the antioxidative effect would be very valuable in studying ROS-related functions of the protein.
But despite all effort, we and other labs did not find such mutants. For PON1, enzymatic activity may give rise to its anti-oxidative role, but our data suggest that this is different for PON2. We also inserted mutations other than the ones reported here (not shown). For instance, PON2-C 283 A and -C 283 V were constructed, as the corresponding residue in PON1 may be involved in its anti-oxidative function. However, this PON2 mutation was hardly tolerated by cells and did not appear to impact on the reported activities. Further, we truncated the amino-terminal residues 1-26, as this region likely represents the membrane attachment site of PON2 such that its deletion may have altered localization and function, but cells did not express it to reasonable levels. We also used the 12 residues shorter isoform-2 of PON2 (9), but this mutant appeared to induce cell cycle arrest for yet unknown reasons (not shown), which confounds analyses of cell death. Given the fact that all named mutants did not impact on ROS, and considering the now characterized antioxidative mechanism of PON2, we argue that PON2, in the simplest model, may act as an insulator for CoQ in order to prevent coincidental superoxide production at the inner mitochondrial membrane, a principal that applies to several proteins (23) . Apparently, this may culminate in cancer, as some tumors could exploit PON2 and enhance its expression to evade ROS-mediated apoptotic signaling (Witte et al., submitted). Together with the fact that PON2 most likely lacks redox-active groups or co-factors (e.g. those present in SODs), this collectively implies that there may not exist such mutant that inhibits PON2's anti-oxidative activity, unless its proposed interaction with CoQ, folding or targeting are disturbed. Most of our understanding on PONs come from PON1, especially due to structural data and functional characteristics (11, 28, 29 Q-GFP overexpressing cells were treated with tunicamycin (1 µg/ml; 24h) and analyzed for intracellular ATP content. A decrease in ATP reports initiation of cell death. (D) Named cells were treated with staurosporine (1 µM; 16h) and analyzed for cell death (Annexin-V; 7-AAD) by flow cytometry. Graphs show relative induction of apoptosis in treated versus untreated cells. n=3-9. n.s.=not significant; *p<0.05; **p<0.01; ***p<0.001.
